am-630 and Huntington-Disease

am-630 has been researched along with Huntington-Disease* in 1 studies

Other Studies

1 other study(ies) available for am-630 and Huntington-Disease

ArticleYear
The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.
    Journal of neuroimmunology, 2014, Feb-15, Volume: 267, Issue:1-2

    Transcriptional dysregulation is a major pathological feature of Huntington's disease (HD). The goal of this study was to understand how p65/RelA co-regulated genes, specifically those of the cytokine and endocannabinoid systems, were affected in HD. p65/RelA levels were lower in human HD tissue and R6/2 HD mice, as were the levels of the type 1 cannabinoid receptor (CB1), IL-1β, IL-8, CCL5, GM-CSF, MIP-1β, and TNFα, all of which may be regulated by p65/RelA. Activation of p65/RelA restored CB1 and CCL5 expression in STHdh cell models of HD. Therefore, p65/RelA activation may normalize the expression of some genes in HD.

    Topics: Adult; Age Factors; Aged; Amidohydrolases; Animals; Arachidonic Acids; Cannabinoids; Cells, Cultured; Corpus Striatum; Cytokines; Disease Models, Animal; Endocannabinoids; Enzyme Inhibitors; Female; Gene Expression Regulation; Humans; Huntingtin Protein; Huntington Disease; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Nerve Tissue Proteins; Neurons; NF-kappa B; Nuclear Proteins; Receptor, Cannabinoid, CB1; Transcription Factor RelA; Trinucleotide Repeats; Young Adult

2014